Adjunctive therapy to diet w/ an HMG-CoA reductase inhibitor (statin) or alone for the reduction of elevated total-C, LDL-C, Apo B triglycerides, non-HDL-C to increase HDL-C in adult & adolescent (10-17 yr) patients w/ primary (heterozygous familial & non-familial) hypercholesterolemia. Adjunctive therapy to diet in combination w/ fenofibrate for the reduction of elevated total-C, LDL-C, Apo B & non-HDL-C in adult patients w/ mixed hyperlipidemia. Administered w/ statin, reduce risk of CV events (CV death, nonfatal MI & stroke, unstable angina hospitalization, or need for revascularization) in patients w/ CHD. Reduce risk of major CV events in patient w/ chronic kidney disease, administered w/ simvastatin. Reduction of elevated total-C & LDL-C levels in adult & adolescent (10-17 yr) patients w/ homozygous familial hypercholesterolemia (HoFH), administered w/ statin. Reduction of elevated sitosterol & campesterol levels in patients w/ homozygous familial sitosterolemia (phytosterolemia), administered w/ diet.